CRG-022

About CARGO Therapeutics

CARGO Therapeutics is focused on developing advanced cell therapies for cancer, with a primary mission to create more durable and effective treatments for patients who have relapsed or are refractory to existing CAR T-cell therapies. The company's core technology, the Switch technology, is designed to enhance CAR T-cell persistence and function while mitigating exhaustion. CARGO became a public company via an IPO in November 2023 and is advancing a pipeline of novel CAR T-cell candidates targeting hematological malignancies.

Therapeutic Areas